In 10 seconds? Bi-specific T cell engagers, or BiTEs, are cutting-edge cancer treatments that are having success in treating some types of blood cancers. Exciting new data on next-generation formulations of these treatments show their promise.
That’s a lot of fancy words. What are BiTEs? They are ingenious products of cellular engineering and are emerging stars in cancer immunotherapies (AKA treatments that boost our immune system to kill cancer). Immunotherapies like BiTEs rely on immune cells called T cells–some of which can be activated to kill cancer under certain conditions.
Try our 7-day free trial and access the full article with citations and resources.